MedPath

Combined Use of a Novel Cardioplegic Formula With MPS ® Using the MiECC in Isolated CABG Versus OPCABG

Completed
Conditions
Complication of Extracorporeal Circulation
Complication of Coronary Artery Bypass Graft
Registration Number
NCT03609723
Lead Sponsor
University Hospital, Basel, Switzerland
Brief Summary

A patient group receiving a novel cardioplegic formula with MPS ® (Myocardial protection system) and using the MiECC (Minimal extracorporeal circulation system) when undergoing coronary artery bypass grafting is compared to a retrospective patient group undergoing Off-pump coronary artery bypass grafting.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2433
Inclusion Criteria
  • CABG using MPS® or OPCABG
Exclusion Criteria
  • use of other colloid solution than Cardioplexol ® for MPS®
  • other inventions than CABG
  • myocardial infarction <7 days before CABG
  • patients denial of data use

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
assessment of cardial biomarkers as high sensitive troponin T (hs-TrT), Creatinkinase (CK) and Creatinkinase myocardial type (CK-MB)perioperative during hospital stay for CABG

high sensitive troponin T (hs-TrT), Creatinkinase, (CK) Creatinkinase myocardial type (CK-MB)

Secondary Outcome Measures
NameTimeMethod
mortality30 days after CABG

death after coronary artery bypass grafting

need for intensive care unitperioperative during hospital stay for CABG

duration of stay at intensive care unit

occurence of dysrhythmiaperioperative during hospital stay for CABG

rhythm disturbance after CABG

Trial Locations

Locations (1)

Herzchirurgie University Hospital Basel

🇨🇭

Basel, Switzerland

Herzchirurgie University Hospital Basel
🇨🇭Basel, Switzerland

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.